History

2006

Foundation of and start-up financing for Marinomed Biotechnologie GmbH as a spin-off of the University of Veterinary Medicine in Vienna

2007

Development of the Carragelose® platform

2008

Market launch of the first Carragelose® product and equity investment by Acropora

2010

Licensing partnership with Boehringer Ingelheim, initially for 54 countries

2011

Approval in 22 additional countries

Development of an independent sales network with outsourced production and logistics begins

2012–2016

Further product launches and sales partnerships

2016

Development of and feasibility study for the Marinosolv® technology platform

2017 

Change of legal form to a stock corporation

Preparation of a phase III clinical study for the flagship product Budesolv

2018

Certification of a new Carragelose® nasal spray with decongestant properties